PharmaDeals Review: Latest Articles
All the latest analysis of deal-making activity in the pharmaceutical and biotechnology sector provided by the experts from the PharmaDeals Review.
- Published on: 2008-10-06 Eli Lilly Wins the ImClone Prize Eli Lilly has become the proud owner of ImClone, successfully outbidding Bristol-Myers Squibb (BMS) and paying nearly US$2 B more than BMS’ original offer in the process. ImClone fitted neatly into both companies’ strategies, though the size of this acquisition shows that Eli Lilly was the more eager out of the two. ImClone does, however, come with some strings attached.
- Published on: 2008-10-03 Genentech and Roche Sign Deal for GlycArt’s Anticancer Antibody Therapy Genentech and Roche have entered into a new deal this month, although not the anticipated acquisition of the biotech by the Swiss giant. Instead the companies have formed a collaboration with GlycArt for the development of its antibody for the potential treatment of CD20-positive B-cell malignancies.
- Published on: 2008-09-30 Merck Heads Back to India for More Anti-Infective Programmes Merck continues to look at countries with emerging markets and promising drug discovery capabilities in its bid to find good drug candidates to populate its pipeline. Its latest agreement with Chennai, India-based Orchid Chemicals and Pharmaceuticals is for the discovery and development of anti-infectives.
- Published on: 2008-09-25 Merck Signs Osteoporosis Deal with Japan Tobacco Since Merck’s patent for Fosamax® (alendronate) expired in early 2008, the company has been seeking to fill the gap in its osteoporosis pipeline. A deal signed with Japan Tobacco for its bone growth stimulator drug, JTT-305, is one of the novel approaches that Merck is pursuing.
- Published on: 2008-09-24 Teva and Kowa to Create Leading Generics Business in Japan Teva and Kowa are to combine their capabilities to establish a leading generic pharmaceutical company in Japan. This is the latest in a series of deals made by Teva designed to rapidly grow its business to meet its ambitious target of doubling its size by 2012.
- Published on: 2008-09-22 Sanofi-aventis Gains Zentiva With Sweeter Offer Czech generics company, Zentiva, accepted a higher takeover offer from sanofi-aventis. The acquisition demonstrates the importance that Sanofi is placing on generics as a way to tap into the emerging markets and forms key component of its future growth strategy.
- Published on: 2008-09-19 Astellas Receives Worldwide Commercial Rights to Major Preclinical Programme Maxygen has entered into a co-development agreement with Astellas for its protein drug programme. The subject of the agreement is MAXY-4, a protein being developed for the lucrative rheumatoid arthritis market and other autoimmune diseases.
- Published on: 2008-09-18 Protherics Agrees to Takeover by BTG BTG is to buy Protherics in stock in a deal that will create one of Britain’s biggest biotech companies. The rationale is to create a ‘sustainably profitable life sciences business’ – one that has the resources to bring drugs to market rather than having to rely on out-licensing deals as is common in the biotech industry.
- Published on: 2008-09-16 Bayer’s Foray into Biotech Bayer has acquired the German biotech company, Direvo, in an all cash deal to bolster its biologicals pipeline. Through its protein engineering platform, Direvo was developing therapeutic antibodies and proteases to treat a range of diseases such as rheumatoid arthritis and Crohn’s disease and blood disorders.
- Published on: 2008-09-12 CV Therapeutics Aims High Through its Agreement with Menarini CV Therapeutics (CVT) has high hopes for its angina drug Ranexa® (ranolazine extended release) after signing over the drug’s commercialisation rights to the Menarini Group in exchange for an upfront fee, milestones and royalties. However, CVT still retains the drug’s rights within the lucrative US and Japanese markets.
Last Issue PDF
RSS